Making the Connections: A Roadmap for Success at the J.P. Morgan Healthcare Conference

Nov 14 2016

Navigating the sea of life science executives and investors at large healthcare conferences can be an intimidating experience. As one of the largest annual conferences of the life science industry, the J.P. Morgan Healthcare Conference, requires strategic planning for those attending. Our panel represents a cross section of expertise from pharma, venture and business in order to provide a comprehensive perspective of key players at the event. Please join Lesley Stolz, William Newell and Shelley Chu in an informative and interactive session on how to plan for and succeed at the J.P. Morgan conference.

Topics covered:

  • Deciding who to meet with at J.P. Morgan
  • How to make the initial connections
  • How to schedule your meetings
  • How to navigate and network at the event

12:15 PM | Registration, Lunch and Networking
1:00 PM | Panel and Q&A
2:00 PM | Program Close

Michael F. Bigham | CEO and Chairman, Paratek read bio»
William J. Newell | CEO, Sutro Biopharma read bio»
Lesley Stolz, Ph.D. | Head, JLABS, CA read bio»

$15 | General Public
$30 | Onsite

329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
Map It

Speakers' Biographies:

Michael F. Bigham | CEO and Chairman, Paratek
Michael F. Bigham was appointed Chief Executive Officer and Chairman of the board of directors of Paratek in June 2014. Mr. Bigham has more than 25 years of senior leadership experience in the biopharmaceutical industry. Since 2003, he has been a Partner at Abingworth LLP, a leading international investment group dedicated to life sciences and healthcare. He currently serves on the boards of Avedro and Secure EDI and has held several directorships, including at Avila Therapeutics (where he was also the founding Chairman and CEO), Magellan Biosciences, Portola Pharmaceuticals, Supernus Pharmaceuticals and Valeritas. Mr. Bigham was formerly Vice Chairman of Corixa Corporation, a publicly traded biotechnology company, and was President and Chief Executive of Coulter Pharmaceuticals, a publicly-traded oncology company, until it merged into Corixa. Previously, he was an early employee at Gilead Sciences where he served in various capacities, including Executive Vice President of Operations and Chief Financial Officer. Before joining Gilead, Mr. Bigham was a Partner at Hambrecht & Quist where he became Co-Head of Healthcare Investment Banking. Mr. Bigham received his B.S. from the University of Virginia and qualified as a C.P.A. before completing his M.B.A. at Stanford University.

William J. Newell | CEO, Sutro Biopharma
Mr. Newell has over 24 years of senior management experience in the biotechnology industry. He joined Sutro Biopharma as CEO in January 2009. Previously, he served as the President of Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell also was Chief Business Officer and Senior Vice President at publicly-traded QLT, Inc. and served in several senior management positions at public-traded Axys Pharmaceuticals, Inc. For the 16 years prior to joining Axys, Mr. Newell practiced corporate law in the San Francisco Bay Area. He is presently a member of the Board at Symic Bio. Mr. Newell is also a Board member on BIO's Emerging Companies Section and a member of the Board and of the Executive Committee of the California Life Sciences Association.
Connect with Bill: Connect on LinkedIn

Lesley Stolz | Head of JLABS, CA, Johnson & Johnson Innovation, JLABS
Dr. Stolz has 20 years of business and corporate development experience working for companies that have been both technology platform and therapeutics focused. After two years negotiating partnering deals for Johnson & Johnson Innovation at the California Innovation Center, Lesley joined the JLABS team as Head of JLABS, CA, to participate in the mission of helping to catalyze new companies in the healthcare ecosystem. Prior to joining Johnson & Johnson Innovation, she held executive positions with BioTime, Inc., Sutro Biopharma, Inc., and Sunesis Pharmaceuticals where she was responsible for corporate strategy, fundraising and all aspects of partnering. Earlier in her career, she served as Senior Director, Business Development for Aerovance, Inc. and for GPC Biotech AG in Munich, Germany from 2002 to 2006. She also served in senior management positions at Cell Genesys, Discovery Partners International and Axys Pharmaceuticals. Dr. Stolz received her Ph.D. in chemistry, and conducted postdoctoral research at Harvard Medical School's Department of Biochemistry and Molecular Pharmacology.
Connect with Lesley : Connect on LinkedIn